ImmunONE Secures £2M Funding for Ethical Drug Testing
Revolutionizing Drug Safety: A New Era of Testing Without Animals
ImmunONE, an innovative biotech company based in Hatfield, UK, is leading a paradigm shift in drug safety assessments by developing a cutting-edge 3D human lung model that eliminates the need for animal testing. Recently, the firm successfully raised £2M in funding to expand its operations and enhance its capabilities. This funding round was spearheaded by the MEIF Proof of Concept & Early Stage Fund, managed by Mercia Ventures, as part of the Midlands Engine Investment Fund. With plans to relocate its headquarters to Milton Keynes and establish new laboratories in Stevenage, ImmunONE is poised to meet the increasing demand for ethical testing solutions and expand its growing team.
At the forefront of this revolutionary approach are Dr.
Abigail Martin and Professor Victoria Hutter, who pioneered the development of the 3D lung model. Their innovative methodology provides a viable alternative to traditional safety assessments that have relied on animal testing and invasive human cell sampling. By cultivating human lower lung tissue and immune cells, ImmunONE's model provides a more accurate and reliable way for companies—ranging from pharmaceuticals to cosmetics—to ensure that their products are safe for human consumption. As a result, this cutting-edge approach not only enhances safety but also meets legal requirements, paving the way for compliance in a rapidly evolving regulatory landscape.
Since its inception in 2019, ImmunONE has made significant strides, accumulating over £1M in revenue and attracting approximately 20 clients globally, including well-known chemical and consumer product firms. These achievements underscore the potential for investment and growth in the biotech sector, particularly for startups focused on sustainable and ethical testing methods. As ImmunONE continues its journey of innovation and expansion, it exemplifies how strategic funding and visionary leadership can reshape the future of healthcare and product safety—all while gaining the attention of investors eager to support ethical practices in the industry.
Key Terms Explained
- 3D human lung model
- An innovative approach developed by ImmunONE which entails a cutting-edge model of the human lung for drug safety testing, thereby eliminating the need for animal testing. The model is designed for cultivating human lower lung tissue and immune cells to provide a more accurate and reliable safety assessment.
- £2M in funding
- The amount of capital that ImmunONE successfully raised to expand its operations and enhance its capabilities. This funding round was led by MEIF Proof of Concept & Early Stage Fund.
- £1M in revenue
- The income that ImmunONE has generated since it was founded in 2019. This figure indicates its potential for investment and growth in the biotech sector, especially for startups focused on ethical, sustainable testing methods.
Frequently Asked Questions
- What is the innovative development that ImmunONE is known for?-ImmunONE is known for developing a cutting-edge 3D human lung model that eliminates the need for animal testing in safety assessments.
- Who are the key people behind this revolutionary approach of drug safety testing?+
- How much funding has ImmunONE raised recently and who spearheaded the funding round?+
- What is ImmunONE's revenue and client base since 2019?+
- What does ImmunONE's approach mean for the investment sector?+
They've invested in ImmunONE
Get to know these Biotech investors
Click here for a full list of 7,526+ startup investors in the UK